Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Patient-reported distress can aid clinical decision-making in idiopathic pulmonary fibrosis: analysis of the PROFILE cohort.

Stewart I, McKeever T, Braybrooke R, Oballa E, Simpson JK, Maher TM, Marshall RP, Lukey PT, Fahy WA, Jenkins G, Saini G.

Eur Respir J. 2019 May 9;53(5). pii: 1801925. doi: 10.1183/13993003.01925-2018. Print 2019 May.

PMID:
30846471
2.

A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis.

Lukey PT, Harrison SA, Yang S, Man Y, Holman BF, Rashidnasab A, Azzopardi G, Grayer M, Simpson JK, Bareille P, Paul L, Woodcock HV, Toshner R, Saunders P, Molyneaux PL, Thielemans K, Wilson FJ, Mercer PF, Chambers RC, Groves AM, Fahy WA, Marshall RP, Maher TM.

Eur Respir J. 2019 Mar 18;53(3). pii: 1801992. doi: 10.1183/13993003.01992-2018. Print 2019 Mar.

PMID:
30765508
3.

Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin αvβ6 inhibitor, in healthy participants.

Maden CH, Fairman D, Chalker M, Costa MJ, Fahy WA, Garman N, Lukey PT, Mant T, Parry S, Simpson JK, Slack RJ, Kendrick S, Marshall RP.

Eur J Clin Pharmacol. 2018 Jun;74(6):701-709. doi: 10.1007/s00228-018-2435-3. Epub 2018 Mar 12.

4.

A Microdose PET Study of the Safety, Immunogenicity, Biodistribution, and Radiation Dosimetry of 18F-FB-A20FMDV2 for Imaging the Integrin αvβ6.

Keat N, Kenny J, Chen K, Onega M, Garman N, Slack RJ, Parker CA, Lumbers RT, Hallett W, Saleem A, Passchier J, Lukey PT.

J Nucl Med Technol. 2018 Jun;46(2):136-143. doi: 10.2967/jnmt.117.203547. Epub 2018 Feb 2.

PMID:
29438002
5.

The topical study of inhaled drug (salbutamol) delivery in idiopathic pulmonary fibrosis.

Usmani OS, Biddiscombe MF, Yang S, Meah S, Oballa E, Simpson JK, Fahy WA, Marshall RP, Lukey PT, Maher TM.

Respir Res. 2018 Feb 6;19(1):25. doi: 10.1186/s12931-018-0732-0.

6.

Pulmonary 18F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF).

Win T, Screaton NJ, Porter JC, Ganeshan B, Maher TM, Fraioli F, Endozo R, Shortman RI, Hurrell L, Holman BF, Thielemans K, Rashidnasab A, Hutton BF, Lukey PT, Flynn A, Ell PJ, Groves AM.

Eur J Nucl Med Mol Imaging. 2018 May;45(5):806-815. doi: 10.1007/s00259-017-3917-8. Epub 2018 Jan 16.

7.

An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study.

Maher TM, Oballa E, Simpson JK, Porte J, Habgood A, Fahy WA, Flynn A, Molyneaux PL, Braybrooke R, Divyateja H, Parfrey H, Rassl D, Russell AM, Saini G, Renzoni EA, Duggan AM, Hubbard R, Wells AU, Lukey PT, Marshall RP, Jenkins RG.

Lancet Respir Med. 2017 Dec;5(12):946-955. doi: 10.1016/S2213-2600(17)30430-7. Epub 2017 Nov 14.

8.

An αv-RGD Integrin Inhibitor Toolbox: Drug Discovery Insight, Challenges and Opportunities.

Hatley RJD, Macdonald SJF, Slack RJ, Le J, Ludbrook SB, Lukey PT.

Angew Chem Int Ed Engl. 2018 Mar 19;57(13):3298-3321. doi: 10.1002/anie.201707948. Epub 2018 Feb 21. Review.

PMID:
28944552
9.

Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF.

Mercer PF, Woodcock HV, Eley JD, Platé M, Sulikowski MG, Durrenberger PF, Franklin L, Nanthakumar CB, Man Y, Genovese F, McAnulty RJ, Yang S, Maher TM, Nicholson AG, Blanchard AD, Marshall RP, Lukey PT, Chambers RC.

Thorax. 2016 Aug;71(8):701-11. doi: 10.1136/thoraxjnl-2015-207429. Epub 2016 Apr 21.

10.

Daily Home Spirometry: An Effective Tool for Detecting Progression in Idiopathic Pulmonary Fibrosis.

Russell AM, Adamali H, Molyneaux PL, Lukey PT, Marshall RP, Renzoni EA, Wells AU, Maher TM.

Am J Respir Crit Care Med. 2016 Oct 15;194(8):989-997.

11.

Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study.

Jenkins RG, Simpson JK, Saini G, Bentley JH, Russell AM, Braybrooke R, Molyneaux PL, McKeever TM, Wells AU, Flynn A, Hubbard RB, Leeming DJ, Marshall RP, Karsdal MA, Lukey PT, Maher TM.

Lancet Respir Med. 2015 Jun;3(6):462-72. doi: 10.1016/S2213-2600(15)00048-X. Epub 2015 Mar 12.

12.

Strategies for biomarker discovery in fibrotic disease.

Marshall RP, Simpson JK, Lukey PT.

Biochim Biophys Acta. 2013 Jul;1832(7):1079-87. doi: 10.1016/j.bbadis.2013.01.018. Epub 2013 Jan 31. Review.

13.

Serodiagnostic markers for the prediction of the outcome of intensive phase tuberculosis therapy.

Baumann R, Kaempfer S, Chegou NN, Nene NF, Veenstra H, Spallek R, Bolliger CT, Lukey PT, van Helden PD, Singh M, Walzl G.

Tuberculosis (Edinb). 2013 Mar;93(2):239-45. doi: 10.1016/j.tube.2012.09.003. Epub 2012 Nov 2.

PMID:
23127778
14.

Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response.

Cliff JM, Lee JS, Constantinou N, Cho JE, Clark TG, Ronacher K, King EC, Lukey PT, Duncan K, Van Helden PD, Walzl G, Dockrell HM.

J Infect Dis. 2013 Jan 1;207(1):18-29. doi: 10.1093/infdis/jis499. Epub 2012 Aug 7.

PMID:
22872737
15.

Ultrasonographic measures of synovitis in an early phase clinical trial: a double-blind, randomised, placebo and comparator controlled phase IIa trial of GW274150 (a selective inducible nitric oxide synthase inhibitor) in rheumatoid arthritis.

Seymour M, Pétavy F, Chiesa F, Perry H, Lukey PT, Binks M, Donatien PD, Freidin AJ, Eckersley RJ, McClinton C, Heath K, Prodanovic S, Radunovic G, Pilipovic N, Damjanov N, Taylor PC.

Clin Exp Rheumatol. 2012 Mar-Apr;30(2):254-61. Epub 2012 Apr 13.

PMID:
22409880
16.

Quantitative power Doppler ultrasonography is a sensitive measure of metacarpophalangeal joint synovial vascularity in rheumatoid arthritis and declines significantly following a 2-week course of oral low-dose corticosteroids.

Larché MJ, Seymour M, Lim A, Eckersley RJ, Pétavy F, Chiesa F, Rioja I, Lukey PT, Binks M, McClinton C, Dolan K, Taylor PC.

J Rheumatol. 2010 Dec;37(12):2493-501. doi: 10.3899/jrheum.100322. Epub 2010 Oct 1.

PMID:
20889600
17.

Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients.

Hesseling AC, Walzl G, Enarson DA, Carroll NM, Duncan K, Lukey PT, Lombard C, Donald PR, Lawrence KA, Gie RP, van Helden PD, Beyers N.

Int J Tuberc Lung Dis. 2010 May;14(5):560-70.

PMID:
20392348
18.

High levels of intracellular IL-4 are expressed in circulating apoptotic T cells in patients with tuberculosis and in community controls.

Veenstra H, Baumann R, Lukey PT, Beyers N, van Helden PD, Walzl G.

Tuberculosis (Edinb). 2008 Jan;88(1):21-30. Epub 2007 Oct 30.

PMID:
17977794
19.

Strain-dependent variation in Mycobacterium bovis BCG-induced human T-cell activation and gamma interferon production in vitro.

Aguirre-Blanco AM, Lukey PT, Cliff JM, Dockrell HM.

Infect Immun. 2007 Jun;75(6):3197-201. Epub 2007 Mar 26.

20.

Gene-expression patterns in whole blood identify subjects at risk for recurrent tuberculosis.

Mistry R, Cliff JM, Clayton CL, Beyers N, Mohamed YS, Wilson PA, Dockrell HM, Wallace DM, van Helden PD, Duncan K, Lukey PT.

J Infect Dis. 2007 Feb 1;195(3):357-65. Epub 2006 Dec 21.

PMID:
17205474
21.

Immune markers measured before treatment predict outcome of intensive phase tuberculosis therapy.

Brahmbhatt S, Black GF, Carroll NM, Beyers N, Salker F, Kidd M, Lukey PT, Duncan K, van Helden P, Walzl G.

Clin Exp Immunol. 2006 Nov;146(2):243-52.

22.

Changes in leucocyte and lymphocyte subsets during tuberculosis treatment; prominence of CD3dimCD56+ natural killer T cells in fast treatment responders.

Veenstra H, Baumann R, Carroll NM, Lukey PT, Kidd M, Beyers N, Bolliger CT, van Helden PD, Walzl G.

Clin Exp Immunol. 2006 Aug;145(2):252-60.

23.

Protein expression by a Beijing strain differs from that of another clinical isolate and Mycobacterium tuberculosis H37Rv.

Pheiffer C, Betts JC, Flynn HR, Lukey PT, van Helden P.

Microbiology. 2005 Apr;151(Pt 4):1139-50.

PMID:
15817781
24.

Differential gene expression identifies novel markers of CD4+ and CD8+ T cell activation following stimulation by Mycobacterium tuberculosis.

Cliff JM, Andrade IN, Mistry R, Clayton CL, Lennon MG, Lewis AP, Duncan K, Lukey PT, Dockrell HM.

J Immunol. 2004 Jul 1;173(1):485-93.

25.

Signature gene expression profiles discriminate between isoniazid-, thiolactomycin-, and triclosan-treated Mycobacterium tuberculosis.

Betts JC, McLaren A, Lennon MG, Kelly FM, Lukey PT, Blakemore SJ, Duncan K.

Antimicrob Agents Chemother. 2003 Sep;47(9):2903-13.

26.

Associations between toll-like receptors and interleukin-4 in the lungs of patients with tuberculosis.

Fenhalls G, Squires GR, Stevens-Muller L, Bezuidenhout J, Amphlett G, Duncan K, Lukey PT.

Am J Respir Cell Mol Biol. 2003 Jul;29(1):28-38. Epub 2002 Dec 30.

PMID:
12600829
27.

In situ detection of Mycobacterium tuberculosis transcripts in human lung granulomas reveals differential gene expression in necrotic lesions.

Fenhalls G, Stevens L, Moses L, Bezuidenhout J, Betts JC, Helden Pv Pv, Lukey PT, Duncan K.

Infect Immun. 2002 Nov;70(11):6330-8.

28.

Characterization of a Mycobacterium tuberculosis H37Rv transposon library reveals insertions in 351 ORFs and mutants with altered virulence.

McAdam RA, Quan S, Smith DA, Bardarov S, Betts JC, Cook FC, Hooker EU, Lewis AP, Woollard P, Everett MJ, Lukey PT, Bancroft GJ, Jacobs WR Jr, Duncan K.

Microbiology. 2002 Oct;148(Pt 10):2975-86.

PMID:
12368431
29.

Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling.

Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K.

Mol Microbiol. 2002 Feb;43(3):717-31.

30.

Distribution of IFN-gamma, IL-4 and TNF-alpha protein and CD8 T cells producing IL-12p40 mRNA in human lung tuberculous granulomas.

Fenhalls G, Stevens L, Bezuidenhout J, Amphlett GE, Duncan K, Bardin P, Lukey PT.

Immunology. 2002 Mar;105(3):325-35.

31.
32.

HLA-B*35-restricted CD8(+)-T-cell epitope in Mycobacterium tuberculosis Rv2903c.

Klein MR, Hammond AS, Smith SM, Jaye A, Lukey PT, McAdam KP.

Infect Immun. 2002 Feb;70(2):981-4.

35.

HLA-B*35-restricted CD8 T cell epitopes in the antigen 85 complex of Mycobacterium tuberculosis.

Klein MR, Smith SM, Hammond AS, Ogg GS, King AS, Vekemans J, Jaye A, Lukey PT, McAdam KP.

J Infect Dis. 2001 Mar 15;183(6):928-34. Epub 2001 Feb 21.

PMID:
11237810
36.

17 macrophage virulence assays.

Lukey PT, Hooker EU.

Methods Mol Med. 2001;54:271-80. doi: 10.1385/1-59259-147-7:271.

PMID:
21341081
37.

Human CD8+ CTL specific for the mycobacterial major secreted antigen 85A.

Smith SM, Brookes R, Klein MR, Malin AS, Lukey PT, King AS, Ogg GS, Hill AV, Dockrell HM.

J Immunol. 2000 Dec 15;165(12):7088-95.

38.

Monocyte-derived macrophage cytokine responses induced by M. bovis BCG.

Atkinson S, Valadas E, Smith SM, Lukey PT, Dockrell HM.

Tuber Lung Dis. 2000;80(4-5):197-207. Erratum in: Tuber Lung Dis 2000;80(6):293.

PMID:
11052909
39.

In situ production of gamma interferon, interleukin-4, and tumor necrosis factor alpha mRNA in human lung tuberculous granulomas.

Fenhalls G, Wong A, Bezuidenhout J, van Helden P, Bardin P, Lukey PT.

Infect Immun. 2000 May;68(5):2827-36.

42.

Prostanoid modulation of synovial antigen-specific CD4+ T-cell cytotoxic function in rheumatoid arthritis.

Ratcliffe LT, Lukey PT, Meyers OL, Ress SR.

Br J Rheumatol. 1995 Feb;34(2):113-20.

PMID:
7535639
43.

Reduced NK activity correlates with active disease in HIV- patients with multidrug-resistant pulmonary tuberculosis.

Ratcliffe LT, Lukey PT, MacKenzie CR, Ress SR.

Clin Exp Immunol. 1994 Sep;97(3):373-9.

44.
46.

Reduced natural killer cell activity in multi-drug resistant pulmonary tuberculosis.

Ratcliffe LT, Mackenzie CR, Lukey PT, Ress SR.

Scand J Immunol Suppl. 1992;11:167-70.

PMID:
1514034
48.

An in-vitro comparison of the intraphagocytic bioactivity of erythromycin and roxithromycin.

Anderson R, Van Rensburg CE, Jooné G, Lukey PT.

J Antimicrob Chemother. 1987 Nov;20 Suppl B:57-68.

PMID:
3429387
49.

Dithranol mediates pro-oxidative inhibition of polymorphonuclear leukocyte migration and lymphocyte proliferation.

Anderson R, Lukey PT, Dippenaar U, Eftychis HA, Findlay GH, Wooten MW, Nel AE.

Br J Dermatol. 1987 Oct;117(4):405-18.

PMID:
3676090
50.

Supplemental Content

Loading ...
Support Center